Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!) (NIP IT!)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The development of anticancer drugs typically starts with patients with advanced cancers who have exhausted standard treatments. Yet even the most active new drugs produce only modest benefits in patients with advanced cancers because of the emergence of resistance, similar to the resistance that bacteria develop when they are repeatedly exposed to antibiotics. In order to achieve larger magnitude gains in survival and make greater impact in the field of cancer, promising drugs must be tested in patients with curable malignancies who have undergone definitive treatment but are at high risk of relapse. Interception is the active intervention of cancers at an early stage, offering an opportunity to eliminate molecular residual disease (MRD) before clinical relapse. MRD describes the situation in which cancer-derived biomarkers are detectable, typically using highly sensitive and specific molecular assays in blood or other body substances that are below the threshold of detection by conventional tests such as CT scans or radiological imaging. Using innovative technologies to monitor patients at high risk of relapse, and applying them to serial samples of their circulating tumor DNA, other body fluids, stool and radiological images, the goal is to develop AI-based models to identify those who are at the highest risk of relapse. This will allow interception studies to be conducted to target microscopic tumor cells in these patients to increase cancer cure rates.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Elizabeth Shah
- Phone Number: 3833 416-946-4501
- Email: elizabeth.shah@uhn.ca
Study Contact Backup
- Name: Celeste Yu, MSc
- Phone Number: 5281 416-946-4501
- Email: celeste.yu@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- Princess Margaret Cancer Centre
-
Contact:
- Celeste Yu
- Phone Number: 5281 416-946-4501
- Email: celeste.yu@uhn.ca
-
Principal Investigator:
- Lillian Siu, MD
-
Principal Investigator:
- Philippe Bedard, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Early stage or locally advanced disease that is planned for or have undergone curative treatment.
Description
Inclusion Criteria:
- Patients with histological confirmation of a solid tumor.
- Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
- Patient must be ≥ 18 years old.
- All patients must have signed and dated an informed consent form.
Exclusion Criteria:
None
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
NIP IT!
Patients with early stage or locally advanced disease that is planned for or have undergone curative treatment will have next-generation sequencing (NGS)-based ctDNA analysis performed on blood samples to determine minimal residual disease (MRD). Blood samples, stool samples, and additional archival/fresh tumor specimens will be collected for banking and future research purposes. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in ctDNA collected from biospecimens
Time Frame: Through study completion, an average of 4 years
|
Next-generation sequencing based ctDNA analysis |
Through study completion, an average of 4 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants that are identified as high risk of clinical relapse with artificial intelligence (AI) and machine learning algorithms
Time Frame: Through study completion, an average of 4 years
|
Through study completion, an average of 4 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lillian Siu, MD, Princess Margaret Hospital, Canada
- Principal Investigator: Philippe Bedard, MD, Princess Margaret Hospital, Canada
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Neoplastic Processes
- Skin Diseases
- Breast Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Skin Neoplasms
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Neoplasm, Residual
- Breast Neoplasms
- Melanoma
- Gastro-enteropancreatic neuroendocrine tumor
Other Study ID Numbers
Other Study ID Numbers
- NIP IT!
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified study data (including genetic data) may be potentially shared with approved research collaborators.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.